ZYDUS WELLNESS LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,786 INR | +2.00% |
|
+1.96% | +4.12% |
| 14/05 | Transcript : Zydus Wellness Limited, Q4 2024 Earnings Call, May 14, 2024 | |
| 14/05 | Zydus Wellness Sees Rise in Fiscal Q4 Consolidated Net Profit | MT |
Strengths
- The company returns high margins, thereby supporting business profitability.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- With an expected P/E ratio at 37.46 and 28.34 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's enterprise value to sales, at 4.78 times its current sales, is high.
- The company is highly valued given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the past year, analysts have significantly revised downwards their profit estimates.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Food Processing
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +4.12% | 131.13Cr | C+ | ||
| -2.02% | 27TCr | A- | ||
| -1.52% | 9.65TCr | C+ | ||
| -3.06% | 4.39TCr | C+ | ||
| +10.17% | 4.22TCr | B- | ||
| +1.60% | 4.12TCr | B- | ||
| +7.20% | 4TCr | B- | ||
| -16.81% | 3.05TCr | B- | ||
| -7.27% | 2.87TCr | A | ||
| +14.53% | 2.55TCr | A- |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- ZYDUSWELL Stock
- Ratings Zydus Wellness Limited